GSK (GSK) DIvidends Date & History

Key Takeaways

• GSK plc provides a forward dividend yield of 3.26%, appealing for income-focused investors in the biopharma sector.
• The company pays dividends quarterly, with the most recent quarterly dividend equivalent to 18p per ordinary share (Q4 2025).
• Payout ratio stands at 46.54%, well below 75%, signaling strong dividend sustainability.
• Dividends are supported by trailing twelve-month (TTM) earnings per share (EPS) of $3.75 and levered free cash flow (FCF, cash generated after capital expenditures) of $3.28 billion.
• Relative to peers like Johnson & Johnson (JNJ) at 2.3%, GSK's yield is competitive, though below Pfizer (PFE)'s higher rate.
• Recent modest dividend increases follow a period of declines tied to strategic restructuring.

Dividend Overview

GSK plc, a leading biopharma company focused on vaccines and specialty medicines, maintains a quarterly dividend policy that delivers reliable income to shareholders. The forward annual dividend is $1.78 per American Depositary Share (ADS), yielding 3.26% at a recent stock price of $54.44. This positions GSK as a modest dividend payer rather than a high-yield or aggressive growth stock. The most recent ex-dividend date was February 20, 2026, with payment on April 9, 2026. GSK's dividend profile emphasizes sustainability over rapid expansion, supported by its diversified portfolio in oncology, HIV, and respiratory treatments. Investors value this consistency in a sector prone to patent cliffs and R&D risks.

Dividend History and Growth

GSK has paid dividends quarterly for decades, but the total annual payout has fluctuated. In GBP for ordinary shares, the 2023 total was 58p, up slightly from 2022's adjusted 61.25p post-share consolidation. Recent quarters show modest growth, with Q4 2025 at 18p versus prior 16p levels. Long-term, dividends declined from peaks over £0.90 in the early 2010s, reflecting the 2022 spin-off of consumer health unit Haleon and R&D investments. No consecutive years of increases qualify it as a dividend aristocrat, but stability has returned, with 2025 full-year at 66p and 2026 expected at 70p.

Dividend Sustainability and Payout Ratio

GSK's dividend appears highly sustainable, with a payout ratio of 46.54%—leaving ample room for reinvestment and buffers against downturns. Earnings comfortably cover payments, as TTM EPS of $3.75 exceeds the $1.78 annual dividend. Free cash flow of $3.28 billion TTM provides robust coverage, while operating cash flow reaches $7.74 billion. Debt stands at $17.79 billion against $3.42 billion in cash, a manageable level for the industry given steady revenues from blockbusters like Shingrix and Dovato. Projected EPS growth to $4.81 in 2026 supports ongoing viability.

Dividend Compared to Industry Peers

In the pharmaceuticals sector, GSK's 3.26% yield exceeds Johnson & Johnson (JNJ)'s 2.3% and Merck (MRK)'s approximately 2.5%, but trails Pfizer (PFE)'s elevated 6-7% amid its price pressures. AbbVie (ABBV) offers around 3-4%. GSK's profile—moderate yield with lower payout ratio—stands out for balance, contrasting higher-yield peers with elevated payouts or litigation risks. This makes it attractive relative to the sector average of 2-4%.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to streamline your research.

Is This Stock Attractive for Dividend Investors?

GSK plc suits conservative income investors prioritizing stability over high yields or rapid growth. Its 3.26% yield, backed by a low 46.5% payout and strong cash flows, appeals to those seeking reliable quarterly payouts in a defensive sector like biopharma. Retirees or portfolios emphasizing healthcare exposure may find GSK fitting, given its coverage of essential vaccines and medicines less vulnerable to economic cycles. However, dividend growth seekers might look elsewhere, as historical trends show modest increases post-restructuring rather than multi-decade streaks. Long-term holders valuing pipeline potential in oncology and immunology could pair it with growth assets, but volatility from drug approvals remains a factor. Overall, it balances yield and safety for moderate-risk income strategies.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations